Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary
Open Access
- 1 May 2023
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 34 (5) , 508-515
Abstract
Background: Emerging data suggest that a treat-to-target approach and early therapeutic intervention using regular objective disease assessment leads to improved outcomes. Our aim was to evaluate the value of objective disease monitoring during regular follow-up in a single tertiary inflammatory bowel disease center. Methods: Consecutive inflammatory bowel disease patients (n = 161, Crohn’s disease: 118/ulcerative colitis: 43; biological therapy: 70%) were included and followed up for 1 year between January and December 2018. Data on clinical disease activity, biomarkers, endoscopy, imaging, outpatient visits, treatment optimization, hospitalization, and surgery were collected. We compared the monitoring strategy according to the clinical activity (remission/flare/post-flare/continuous activity) every 3 months (assessment period). Results: In total, n = 644 assessment periods were evaluated. Biomarkers were evaluated in 82.9%-83.9% of patients in each assessment period regardless of clinical activity. Colonoscopy was more frequently performed in active disease (flare/continuous disease activity: 21.1%/18.9% vs. clinical remission: 10.1% per assessment period). Magnetic resonance imaging was performed in 7.7%-16.7%/ period in Crohn’s disease patients, while the use of computed tomography was low (2.4%/period) and mainly performed in active disease. Treatment optimization was more frequent in patients with active disease (biological start/dose optimization: 31.1%/33.8%/ period, steroid start: 13.2%/period). Patients with continuous activity (2.62), flare (2.45), and post-flare (2.05) had higher mean patient visit counts compared to remission (1.68/period). Conclusions: Objective monitoring strategy was applied with routine assessment of clinical activity and biomarkers. Fast-track colonoscopic evaluations were adapted to the clinical stage of the disease while screening colonoscopies and magnetic resonance imaging were frequently used. Objective monitoring resulted in the early optimization of medical therapy and frequent specialist follow-up visits. Cite this article as: Lontai L, Kürti Z, Gonczi L, et al. Objective disease monitoring strategies from a tertiary inflammatory bowel disease center in Hungary. Turk J Gastroenterol. 2023;34(5):508-515.Keywords
This publication has 16 references indexed in Scilit:
- Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinicDigestive and Liver Disease, 2019
- Optimizing Patient Management in Crohn’s Disease in a Tertiary Referral Center: the Impact of Fast-Track MRI on Patient Management and OutcomesJournal of Gastrointestinal and Liver Diseases, 2018
- Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?World Journal of Gastroenterology, 2018
- Limited uptake of ulcerative colitis “treat‐to‐target” recommendations in real‐world practiceJournal of Gastroenterology and Hepatology, 2018
- Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policiesDigestive and Liver Disease, 2018
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialThe Lancet, 2017
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch DisordersJournal of Crohn's and Colitis, 2017
- 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical ManagementJournal of Crohn's and Colitis, 2016
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetAmerican Journal of Gastroenterology, 2015
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006